The Howard Gilman Institute for Valvular Heart Disease
blank top line
home
heart valve disease
patient care
about the institute
research
conference
in the news
contact us
contact us

Research

IN THIS SECTION

1. Overview

2. Research Focus

3. Projects

4. Publications

 

Publications

Books

Borer JS, Isom OW (Editors and authors).
Pathophysiology, Evaluation and Management of Valvular Heart Diseases, Volume II. Advances in Cardiology, 2004: 41: 1-190, Karger (Basel).

Borer, JS, Contemporary Diagnosis and Management of Valvular Heart Diseases, Handbooks in Health Care, Newtown PA (2003), 277 pp.

Borer JS, Isom OW (Eds.).
Pathophysiology, Evaluation and Management of Valvular Heart Diseases, Volume II, Advances in Cardiology, 2002; 39:1-217, Karger (Basel).

Borer JS, Somberg J. (eds and authors) Cardiovascular Drug Development, Marcel Dekker, (New York), 1999.

Journal Articles & Book Chapters

2008 - 2009 1994 - 1995 1985 - 1986
2006 - 2007 1992 - 1993 1983 - 1984
2004 - 2005 1990 - 1991 1980 - 1982
2000 - 2003 1988 - 1989 1978 - 1979
1996 - 1999 1987 1968 - 1977

 

Articles in Preparation, Drafts Complete, Awaiting Submission or Submitted

Hochreiter CH, Borer JS, Supino PG, Kligfield P, Herrold EM, BouRaad D, Yin A, Krieger K, Isom OW. Predictive value of early post-operative non-sustained ventricular tachycardia  for survival late after surgery for non-ischemic mitral regurgitation and modulating effects of right and left ventricular ejection fractions. In draft for submission to J Am Coll Cardiol. (original research)

Cucherat M, Borer JS. Reduction of resting heart rate with antianginal drugs: review and meta-analysis, in final draft prior to submission (original research)

Borer JS, Tardif J-C. Efficacy of ivabradine, a selective If inhibitor, in diabetic patients with chronic stable angina, American Journal of Cardiology, submitted  (original research)

Tendera M, Borer JS, Tardif J-C. Efficacy of If inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology, submitted (original research)

Geller N, Gordon D, Zannad F, Wedel H, Borer JS. Who should know what during the course of a clinical trial? In final draft prior to submission.

< Prev Next >

 

blank
heart valve disease | patient care | about the institute | research | conference | news | contact us
The Howard Gilman Institute for Heart Valve Disease